Recombinant human thrombopoietin clinical development.

D. V. Jones, M. Ashby, S. Vadhan-Raj, G. Somlo, R. Champlin, J. Gajewski, S. Hellmann, G. Fyfe

    Research output: Contribution to journalArticle

    5 Scopus citations


    Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions. Frequent platelet transfusions can cause alloimmunization which requires HLA-matched donors and more frequent blood transfusions, and transmission of both viral and bacterial infections via platelet transfusions remains a concern. Furthermore, thrombocytopenia can mandate a decrease in the dose intensity of cytotoxic therapy by causing either delays or dose reductions in therapy administration. An intervention that reduces the risk or shortens the duration of severe thrombocytopenia would represent an important medical advance. Thrombopoietin (TPO), a naturally occurring, glycosylated polypeptide that was cloned by Genentech in 1994, is capable of inducing differentiation of stem cells into megakaryocytes and accelerating the maturation of megakaryocytes, thereby increasing the platelet count. Recombinant human TPO (rHuTPO) is currently undergoing testing in phase 1 and 2 studies in patients receiving myelosuppressive or myeloablative therapy. For the purposes of illustration, preliminary safety and activity data from one ongoing phase 1 myelosuppression trial (rHuTPO in women with advanced gynecologic malignancies receiving carboplatin) and one ongoing phase 1 myeloablation trial (rHuTPO for peripheral blood progenitor cell mobilization prior to myeloablative chemotherapy for high risk breast cancer) will be presented.

    Original languageEnglish (US)
    Pages (from-to)199-206
    Number of pages8
    JournalStem cells (Dayton, Ohio)
    Volume16 Suppl 2
    StatePublished - 1998

    ASJC Scopus subject areas

    • Molecular Medicine
    • Developmental Biology
    • Cell Biology

    Fingerprint Dive into the research topics of 'Recombinant human thrombopoietin clinical development.'. Together they form a unique fingerprint.

  • Cite this

    Jones, D. V., Ashby, M., Vadhan-Raj, S., Somlo, G., Champlin, R., Gajewski, J., Hellmann, S., & Fyfe, G. (1998). Recombinant human thrombopoietin clinical development. Stem cells (Dayton, Ohio), 16 Suppl 2, 199-206.